Clinical Trial Update: Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema [Phase 3]

View source ↗

Summary

Expanded access program update for lanadelumab in Japanese patients with hereditary angioedema; Phase 3 study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Lanadelumab (lanadelumab)

Snippet

Sponsor: Takeda | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2023-06-26